Gonadorelin Acetate
FDA-approved product (injectable, injection), marketed as Lutrepulse Kit, Factrel.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Gonadorelin Acetate. Its therapeutic class is shown instead.
- WHO therapeutic group
- Gonadotropin-releasing hormones; Tests for fertility disturbances
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Gonadorelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
NCT00500110 · start 2003-06
Registered record
- Registry ID
- NCT00500110
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel; Imatinib Mesylate; Leuprolide; Goserelin Acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2010-02
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDocetaxel; Imatinib Mesylate; Leuprolide; Goserelin AcetatePhasePhase 2Registry statusCompletedALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
NCT00063310 · start 2003-03
Registered record
- Registry ID
- NCT00063310
- Conditions
- Alzheimer Disease
- Interventions
- Leuprolide acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2006-02
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlzheimer DiseaseInterventionLeuprolide acetatePhasePhase 2Registry statusCompletedLupron Sex Offender Therapy
NCT00220350 · start 2001-10
Registered record
- Registry ID
- NCT00220350
- Conditions
- Pedophilia
- Interventions
- leuprolide acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Unknown
- Start
- 2001-10
- Completion
- 2005-08
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPedophiliaInterventionleuprolide acetatePhasePhase 2 / Phase 3Registry statusUnknownRaloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
NCT00031850 · start 2000-03
Registered record
- Registry ID
- NCT00031850
- Conditions
- Breast Cancer
- Interventions
- goserelin acetate; raloxifene
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2000-03
- Completion
- 2007-05
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventiongoserelin acetate; raloxifenePhaseNot applicableRegistry statusCompletedA Treatment Study for Premenstrual Syndrome (PMS)
NCT00001259 · start 1992-08-11
Registered record
- Registry ID
- NCT00001259
- Conditions
- Premenstrual Syndrome; Menstruation Disturbances
- Interventions
- Leuprolide; Estradiol Patches; Progesterone; Placebo patch; Placebo injection; Placebo suppository
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-08-11
- Completion
- 2020-02-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPremenstrual Syndrome; Menstruation DisturbancesInterventionLeuprolide; Estradiol Patches; Progesterone; Placebo patch +2 morePhasePhase 1Registry statusCompleted